Imidapril
- Generic Name
- Imidapril
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H27N3O6
- CAS Number
- 89371-37-9
- Unique Ingredient Identifier
- BW7H1TJS22
- Background
Imidapril has been investigated for the treatment of Kidney, Polycystic, Autosomal Dominant.
- Indication
用于治疗原发性高血压、肾实质性病变所致的继发性高血压。
- Associated Conditions
- Hypertension, Essential Hypertension
- Associated Therapies
- -
Antiproteinuric Effect of Imidapril Versus Ramipril in Type 2 Diabetic and Hypertensive Patients With Microalbuminuria
Phase 3
- Conditions
- Interventions
- First Posted Date
- 2010-10-28
- Last Posted Date
- 2010-10-28
- Lead Sponsor
- University of Pavia
- Target Recruit Count
- 206
- Registration Number
- NCT01230034
- Locations
- 🇮🇹
University of Pavia, Pavia, Italy
Efficacy and Safety Study of Second-Line Treatment for Hypertension With Autosomal Dominant Polycystic Kidney Disease(ADPKD)
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2009-04-29
- Last Posted Date
- 2009-12-02
- Lead Sponsor
- Ministry of Health, Labour and Welfare, Japan
- Target Recruit Count
- 160
- Registration Number
- NCT00890279
- Locations
- 🇯🇵
Division of Kidney and Hypertension, Department of Internal Medicine, Jikei University School of Medicine, Minato-ku, Tokyo, Japan
🇯🇵Department of Medicine II, Nippon Medical School, Bunkyo-ku, Tokyo, Japan
🇯🇵Department of Urology, Teikyo University School of Medicine, Itabashi-ku, Tokyo, Japan
Imidapril and Candesartan on Fibrinolysis and Insulin-Sensitivity in Patients With Mild to Moderate Hypertension
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2008-03-26
- Lead Sponsor
- University of Pavia
- Target Recruit Count
- 60
- Registration Number
- NCT00644475
- Locations
- 🇮🇹
University of Pavia, Pavia, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath